Notice of Proposed Sale · 144
Allogene Therapeutics, Inc.
ALLONASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Allogene Therapeutics, Inc.
- Issuer CIK
- 0001737287
- SEC file number
- 001-38693
- Phone
- (650) 457-2700
- Person for whose account securities are to be sold
- Douglas Earl Martin
- Relationships to issuer
- Officer
- Street
- 210 EAST GRAND AVENUE
- City
- SOUTH SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94080
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 29,697 | 62,957.64 | 345,490,881 | 08/21/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 08/20/2026 | Vesting of restricted stock unit award | Allogene Therapeutics, Inc | 81,719 | N | 08/20/2026 | Granted as part of issuer equity compensation plan |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/21/2026
- Signed
- Douglas Earl Martin
Company context
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.